AD

Financial statements Apteka Pod Wagą

Balance sheet of Apteka Pod Wagą

Company age:
Age:
10 y. 3 m. 13 d.
Share capital:
Share capital:
100 000 PLN

Balance sheet data of APTEKA POD WAGĄ

Year
2018
2019
2020
2021
2022
2023
2024
2025
Total assets 855 876,22 959 772,47 826 358,53 965 220,84 661 233,94 2 439 016,61 2 018 815,38 1 654 679,22
A. Fixed assets 14 345,69 10 286,18 6 940,57 4 660,00 583,41 101 076,16 71 819,08 59 819,97
B. Current assets 841 530,53 949 486,29 819 417,96 960 560,84 660 650,53 2 337 940,45 1 946 996,30 1 594 859,25
C. Share capital contributions (basic funds) 0,00 0,00 0,00 0,00 0,00 - 0,00 -
D. Own shares (stocks) 0,00 0,00 0,00 0,00 0,00 - 0,00 0,00
Total liabilities 855 876,22 959 772,47 826 358,53 965 220,84 661 233,94 2 439 016,61 2 018 815,38 1 654 679,22
A. Equity 260 969,78 382 556,36 441 263,74 504 857,46 547 529,73 -1 070 056,30 -2 377 913,42 -586 403,71
B. Liabilities and provisions for liabilities 594 906,44 577 216,11 385 094,79 460 363,38 113 704,21 3 509 072,91 4 396 728,80 2 241 082,93
I. Long-term liabilities 0,00 0,00 0,00 50 000,00 0,00 1 737 078,62 2 577 629,24 134 342,03
II. Short-term liabilities 524 784,49 513 429,74 384 645,66 343 153,25 113 704,21 1 730 285,72 1 762 658,58 2 065 938,84
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.

  • Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
  • Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
  • Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
  • Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
  • Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
  • Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.
AD
AD